Tackling drug resistance must become biotech’s next frontier
We must treat drug resistance as a central scientific priority rather than an unavoidable complication.
Tackling drug resistance must become biotech’s next frontier Read More »
We must treat drug resistance as a central scientific priority rather than an unavoidable complication.
Tackling drug resistance must become biotech’s next frontier Read More »
Surgeons have performed initial implants of the Mosaic Neo valve at centers across the U.S., and the first robotic implantation has also been performed.
Medtronic wins FDA approval for updated mitral replacement valve Read More »
Native, Hispanic and Black communities experienced worse health access and affordability issues than white people in most states, according to a new report from the Commonwealth Fund.
Health disparities persist across states and may widen further with federal cuts: report Read More »
Strong growth in immunology and neurology prompted AbbVie to raise its 2026 outlook and consider future M&A from a position of “ample financial capacity.”
AbbVie tops Q1 estimates, raises outlook and discontinues cancer candidate Read More »
La inteligencia artificial se ha convertido en una de las grandes prioridades para empresas de todos los tamaños. En pocos años, tecnologías como los asistentes conversacionales, los agentes de IA, los sistemas de análisis de datos, la automatización de procesos o …
During a high-profile congressional hearing on Tuesday, one lawmaker said hospitals charge “an insane amount” for care. Still, the CEOs largely passed the buck, arguing their prices are justified.
Health system CEOs in hot seat over their role in raising healthcare prices Read More »
A weaker-than-expected respiratory season paired with winter storms caused UHS’ volumes to decline in the first quarter. Executives said they expect growth in the second half will help the operator meet earnings targets this year.
UHS reaffirms 2026 volume targets, despite seasonal hits in Q1 Read More »
Humana’s foremost priority is returning to 3% Medicare Advantage margins in 2028, CEO Jim Rechtin promised investors time and time again on Wednesday morning. Still, the insurer’s profits dipped in the first quarter.
Profit recovery is ‘priority No. 1,’ Humana promises Read More »
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer’s market as patients end their 18-month course of Lilly’s product.
Biogen ready to catch Alzheimer’s patients transitioning off Lilly’s Kisunla Read More »
Regeneron hauled in $3.6 billion during the first quarter of 2026, as analysts homed in on a slight Eylea HD miss and key upcoming readouts, including for LAG3 candidate fianlimab in metastatic melanoma.